Hubei Goto Biopharm Group Co., Ltd. (SHE:300966)
China · Delayed Price · Currency is CNY 24.85
+0.10 (0.40%)
Nov 5, 2026, 3:04 PM CST
Hubei Goto Biopharm Group Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Equivalents | 108.43 | 85.85 | 141.18 | 181.97 | 438.42 | 209.91 |
Trading Asset Securities | - | 0 | 0 | 0 | 15.01 | 0.1 |
Cash & Short-Term Investments | 108.43 | 85.85 | 141.18 | 181.97 | 453.43 | 210.02 |
Cash Growth | 14.55% | -39.19% | -22.42% | -59.87% | 115.90% | 625.10% |
Accounts Receivable | 216.25 | 189.1 | 214.26 | 235.4 | 269.36 | 243.86 |
Other Receivables | 4.52 | 3.3 | 2.05 | 2.15 | 1.88 | 2.09 |
Receivables | 220.77 | 192.4 | 216.31 | 237.54 | 271.25 | 245.95 |
Inventory | 535.56 | 473.76 | 384.8 | 396.16 | 432.5 | 371.24 |
Prepaid Expenses | - | - | - | - | - | 1.68 |
Other Current Assets | 47.85 | 18.28 | 27.7 | 54.06 | 56.56 | 29.37 |
Total Current Assets | 912.6 | 770.29 | 770 | 869.73 | 1,214 | 858.26 |
Property, Plant & Equipment | 1,842 | 1,883 | 1,849 | 1,391 | 610.94 | 256.57 |
Long-Term Investments | 42.45 | 48.29 | 48.27 | 48.24 | 48.08 | 14.47 |
Other Intangible Assets | 52.74 | 53.79 | 49.88 | 51 | 43.14 | 27.82 |
Long-Term Deferred Tax Assets | 73.85 | 62.77 | 37.29 | 22.62 | 17.89 | 8.82 |
Long-Term Deferred Charges | 4.08 | 6.56 | 9.69 | 13.3 | 13.96 | 0.97 |
Other Long-Term Assets | 27.01 | 26.31 | 25.78 | 51.96 | 121.56 | 44.34 |
Total Assets | 2,955 | 2,851 | 2,790 | 2,448 | 2,069 | 1,211 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Accounts Payable | 523.1 | 461.26 | 459.91 | 532.24 | 205.52 | 138.17 |
Accrued Expenses | 8.94 | 10.2 | 12.4 | 9.25 | 9.58 | 7.51 |
Short-Term Debt | 211.66 | 229.75 | 294.3 | 110.09 | 321.63 | 143.41 |
Current Portion of Long-Term Debt | - | 95.35 | 24.55 | 22.27 | 5.24 | - |
Current Portion of Leases | - | - | 0.06 | 0.45 | 1.98 | 11.47 |
Current Income Taxes Payable | - | - | 0.08 | 2.8 | 7.21 | 11.27 |
Current Unearned Revenue | 10.99 | 6.59 | 1.23 | 3.47 | 2.01 | 3.7 |
Other Current Liabilities | 118.69 | 18.93 | 15.16 | 5.84 | 22.79 | 17.65 |
Total Current Liabilities | 873.38 | 822.08 | 807.69 | 686.41 | 575.97 | 333.18 |
Long-Term Debt | 1,041 | 974.16 | 812.64 | 652.37 | 437.04 | - |
Long-Term Leases | 0.11 | - | - | 0.54 | 4.41 | 6.67 |
Long-Term Unearned Revenue | 187.42 | 144.06 | 150.25 | 84.33 | 69.71 | 42.98 |
Long-Term Deferred Tax Liabilities | 0.37 | 0.98 | 0.01 | 0.29 | 0.97 | 0 |
Other Long-Term Liabilities | 0.02 | 0.02 | 4.65 | 0.03 | 0.05 | - |
Total Liabilities | 2,103 | 1,941 | 1,775 | 1,424 | 1,088 | 382.83 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Common Stock | 115.28 | 115.28 | 115.28 | 115.28 | 115.28 | 115.28 |
Additional Paid-In Capital | 412.41 | 409.02 | 410.6 | 410.77 | 409.11 | 409.11 |
Retained Earnings | 173.51 | 227.41 | 300.77 | 330.2 | 307.2 | 282.67 |
Treasury Stock | -21.97 | -21.97 | - | - | - | - |
Comprehensive Income & Other | 96.48 | 96.48 | 96.49 | 96.49 | 96.51 | - |
Total Common Equity | 775.71 | 826.22 | 923.14 | 952.75 | 928.09 | 807.05 |
Minority Interest | 76.4 | 83.14 | 91.5 | 71.03 | 53.07 | 21.36 |
Shareholders' Equity | 852.11 | 909.36 | 1,015 | 1,024 | 981.16 | 828.42 |
Total Liabilities & Equity | 2,955 | 2,851 | 2,790 | 2,448 | 2,069 | 1,211 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Total Debt | 1,253 | 1,299 | 1,132 | 785.73 | 770.3 | 161.54 |
Net Cash (Debt) | -1,145 | -1,213 | -990.37 | -603.75 | -316.87 | 48.47 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share | -9.97 | -10.59 | -8.61 | -5.25 | -2.76 | 0.46 |
Filing Date Shares Outstanding | 121.87 | 114.21 | 115.28 | 115.28 | 115.28 | 115.28 |
Total Common Shares Outstanding | 121.87 | 114.21 | 115.28 | 115.28 | 115.28 | 115.28 |
Working Capital | 39.22 | -51.79 | -37.69 | 183.33 | 637.76 | 525.08 |
Book Value Per Share | 6.36 | 7.23 | 8.01 | 8.26 | 8.05 | 7.00 |
Tangible Book Value | 722.97 | 772.43 | 873.26 | 901.75 | 884.95 | 779.23 |
Tangible Book Value Per Share | 5.93 | 6.76 | 7.58 | 7.82 | 7.68 | 6.76 |
Buildings | - | 800.28 | 506.33 | 129.73 | 108.67 | 95.53 |
Machinery | - | 1,029 | 820.79 | 207.89 | 196.16 | 180.78 |
Construction In Progress | - | 333.59 | 694.41 | 1,182 | 411.99 | 66.38 |